| |
IDX719, HCV NS5A Inhibitor, Demonstrates Pan-Genotypic Activity after Three Days of Monotherapy in Genotype 1, 2, 3 or 4 HCV-Infected Subjects
|
| |
| |
Reported by Jules Levin
American Association for the Study of Liver Diseases; Boston, MA; November 9-13, 2012
D. Mayers1, B. Vince2, J. Hill3, E. Lawitz4, W. O'Riordan5, L. Webster6, D. Gruener7, R.S. Mofsen8, A. Murillo9, E. Donovan1, J. Chen1, J.F. McCarville1, J. Z. Sullivan-Bolyai1 and X.J. Zhou1
1Idenix Pharmaceuticals, Inc., Cambridge, MA; 2Vince and Associates Clinical Research, Overland Park, KS; 3Avail Clinical Research, DeLand, FL; 4Alamo Medical Research, San Antonio, TX; 5eStudySite, San Diego, CA; 6Lifetree Clinical Research, Salt Lake City, UT; 7CRI Worldwide, Philadelphia, PA; 8St. Louis Clinical Trials, St. Louis, MO; 9AMPM Research Clinic, Miami, FL
|
|
| |
| |
|
|
|
